Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 1

2(33.3%)

6Total

N/A(4)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07051707Not ApplicableRecruiting

Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD

Role: lead

NCT03639051Not ApplicableActive Not Recruiting

Evaluation of the Safety and Efficacy of TLD in Patients with COPD

Role: lead

NCT02058459Not ApplicableCompleted

Targeted Lung Denervation for Patients With Moderate to Severe COPD

Role: lead

NCT02872298Not ApplicableTerminated

Evaluating the Safety and Feasibility of TLD for the Treatment of Severe Asthma

Role: lead

NCT03213080Withdrawn

Discovery of the Impact of Targeted Lung Denervation (TLD) on the Severe and Very Severe COPD Population

Role: lead

NCT01716598Phase 1Completed

Evaluation of the IPS System for TLD Therapy in Patients With COPD

Role: lead

NCT01483534Phase 1Completed

Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation

Role: lead

All 7 trials loaded